What Is the KLOW Blend?
The KLOW Blend is a four-peptide research compound that combines four complementary peptides in a single vial: GHK-Cu (50mg), a copper-binding tripeptide with a long dermatological research history; BPC-157 (10mg), a synthetic pentadecapeptide studied for tissue and vascular repair; TB-500 (10mg), a synthetic fragment of Thymosin beta-4 investigated for actin regulation and angiogenesis; and KPV (10mg), the anti-inflammatory C-terminal tripeptide of alpha-MSH.
KLOW extends the three-peptide Glow blend (GHK-Cu, BPC-157, TB-500) by adding KPV's anti-inflammatory signal. The design rationale is to target several regenerative and anti-inflammatory pathways in parallel: copper-mediated dermal remodeling, cytoprotective and vascular signaling, actin-driven tissue regeneration, and NF-kB-directed inflammation control. Each component is a research compound; none is an approved drug.
Peptide Profile
Product: KLOW Blend (four-peptide research compound)
Components: GHK-Cu 50mg · BPC-157 10mg · TB-500 10mg · KPV 10mg
GHK-Cu: Copper-binding tripeptide (Gly-His-Lys), ~404 Da
BPC-157: 15-residue peptide, ~1,419 Da
TB-500: synthetic peptide based on the actin-binding region of Thymosin beta-4 (a 43-residue, ~4,921 Da protein)
KPV: Anti-inflammatory tripeptide (Lys-Pro-Val), ~342 Da
Mechanism of Action
KLOW combines four peptides that operate through distinct but complementary pathways spanning dermal remodeling, tissue repair, and inflammation control.
GHK-Cu: Copper Transport & Dermal Remodeling
GHK-Cu is a tripeptide (Gly-His-Lys) with high affinity for copper(II) ions. Research has shown it facilitates copper transport into cells, modulates expression of a large number of genes in dermal fibroblasts, and promotes collagen, elastin, and glycosaminoglycan synthesis, giving it a well-established position in dermatological peptide research.
BPC-157: Cytoprotection & Vascular Signaling
BPC-157 is a 15-amino-acid sequence derived from a protective protein in human gastric juice. Preclinical research has described angiogenic effects, modulation of the nitric oxide system, and accelerated repair of soft tissues including tendon, ligament, muscle, and gastrointestinal mucosa, targeting the connective-tissue side of regeneration in this blend.
TB-500: Actin Regulation & Angiogenesis
TB-500 is a synthetic fragment of Thymosin beta-4, a protein involved in cell migration and wound repair. Its primary mechanism is actin sequestration, which regulates cell motility; research has also described promotion of new blood-vessel formation and reduced inflammation in soft-tissue and cardiac injury models.
KPV: NF-kB-Directed Inflammation Control
KPV is the C-terminal tripeptide of alpha-MSH. Research indicates it suppresses NF-kB signaling and reduces pro-inflammatory cytokine output through a melanocortin-receptor-independent, intracellular route, adding an anti-inflammatory dimension distinct from the regenerative signals of the other three components.
Research Overview
Each component of the KLOW blend has its own research base. The table summarizes key preclinical research areas across the four peptides.
| Research Area | Key Findings | Study Type |
|---|---|---|
| Skin & Collagen (GHK-Cu) | Studies demonstrate stimulation of collagen, elastin, and glycosaminoglycan synthesis and improved dermal density | In vitro & in vivo (human) |
| Wound Healing (GHK-Cu) | Published research documents accelerated wound closure, antioxidant activity, and reduced inflammation in dermal models | In vivo (animal/human) |
| Tissue Repair (BPC-157) | Preclinical studies describe accelerated healing of tendon, ligament, muscle, and GI tissue in rodent injury models | In vivo (rodent) |
| Actin & Repair (TB-500) | Research documents actin sequestration, enhanced cell migration, and pro-angiogenic activity in soft-tissue models | In vitro & in vivo |
| Intestinal Inflammation (KPV) | KPV reduced chemically-induced colonic inflammation in mice via PepT1-mediated uptake into colonocytes | In vivo (rodent) |
| NF-kB / Cytokine Modulation (KPV) | Melanocortin peptides suppressed stimulus-induced NF-kB signaling and pro-inflammatory cytokine output in vitro | In vitro |
The KLOW components collectively carry one of the deepest research footprints of any peptide stack, but the blend itself has not been studied as a combined formulation; the evidence base is the sum of the individual components' preclinical literature. As with all such blends, combined effects are inferred from component mechanisms rather than demonstrated for the four-peptide mixture.
Common Areas of Research Interest
Research interest in the KLOW components spans regenerative and anti-inflammatory domains.
- Skin quality and dermal remodeling, driven primarily by the GHK-Cu copper-peptide research base
- Soft-tissue and connective-tissue repair, the BPC-157 and TB-500 tissue-regeneration literature
- Angiogenesis and vascular signaling, shared research interest across BPC-157 and TB-500
- Inflammation control, KPV's NF-kB-directed anti-inflammatory activity, strongest in intestinal models
- Combined regenerative research, interest in whether stacked, complementary signals broaden regenerative coverage
- Aesthetic and recovery research, the applied context in which these peptides are most often studied together
Comparison to Related Blends
KLOW is most directly compared with the Glow blend, from which it is extended, and its individual components.
| Feature | KLOW | Glow Blend | Wolverine Blend |
|---|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500, KPV | GHK-Cu, BPC-157, TB-500 | BPC-157, TB-500 |
| Added vs Glow | Adds KPV (anti-inflammatory) | Base three-peptide stack | Two-peptide repair core |
| Primary Focus | Skin, repair, and inflammation | Skin remodeling and repair | Soft-tissue repair |
| Anti-Inflammatory Arm | Explicit (KPV) | Indirect (BPC-157/TB-500) | Indirect (BPC-157/TB-500) |
| Peptide Count | 4 | 3 | 2 |
Frequently Asked Questions
Sources & References
- Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018;19(7):1987. PubMed
- Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." Biomed Res Int. 2015;2015:648108. PubMed
- Chang CH, Tsai WC, Lin MS, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol (1985). 2011;110(3):774-80. PubMed
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2011;17(16):1612-32. PubMed
- Malinda KM, Sidhu GS, Mani H, et al. "Thymosin beta4 accelerates wound healing." J Invest Dermatol. 1999;113(3):364-8. PubMed
- Goldstein AL, Hannappel E, Kleinman HK. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-9. PubMed
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-78. PubMed
- Brzoska T, Luger TA, Maaser C, et al. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocr Rev. 2008;29(5):581-602. PubMed
Explore the KLOW Blend
Available for research purposes. Third-party tested for purity and identity.
View KLOW Blend — $175This product is intended for research and laboratory use only. It is not intended for human consumption.